GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
CN Stock MarketDetailed Quotes
688767 Hangzhou Biotest Biotech
- 35.50
- -0.27-0.75%
Market Closed Jan 24 15:00 CST
3.79BMarket Cap36.30P/E (TTM)
36.47High35.33Low9.16KlotVolume36.36Open35.77Pre Close32.66MTurnover0.86%Turnover Ratio35.54P/E (Static)106.67MShares36.4752wk High1.63P/B3.79BFloat Cap20.9552wk Low42.92Limit Up106.67MShs Float146.02Historical High28.62Limit Down3.19%Amplitude20.95Historical Low1.30Dividend TTM35.68Avg Price4.78KlotAsk3.66%Div YieldTTM100Lot Size4.06KlotBid
Hangzhou Biotest Biotech News
Botuo Biotech: Botuo Biotech\'s 2024 annual results forecast
Botuo Biotech 2024 Annual Results Forecast
Botao Biotechnology (688767.SH): Net income is expected to increase by approximately 59.47% in 2024.
On January 23, Gelonghui reported that Botao Biotechnology (688767.SH) announced its annual earnings forecast for 2024. According to preliminary calculations by the finance department, it is expected that the net income attributable to the parent company's owners will be around 170 million yuan in 2024, an increase of approximately 59.47% year-on-year. The net income attributable to the parent company's owners after deducting non-recurring gains and losses is expected to be around 119 million yuan, an increase of approximately 49.83% year-on-year. The company continues to focus on the POCT in-vitro diagnostics sub-industry, effectively grasping customer needs and actively expanding domestic and international markets.
Bohuo Bio (688767.SH) will distribute 5 yuan for every 10 shares in the first three quarters, with the equity registration date on January 9.
Bote Biological (688767.SH) issued an announcement that the company will implement equity distribution for the first three quarters of 2024, with each share...
Net income sharply declined with the contraction of overseas sales, Botai Biology opens up the microfluidic testing field | Earnings conference
①The rapid decline in overseas income dragged down the performance of Botuo Life Sciences, with overall revenue significantly decreasing compared to before the epidemic, and net income attributable to shareholders has decreased year-on-year for multiple years; ② Considering changes in the external environment, Botuo Life Sciences has terminated two major core investment projects, added the Microfluidic Fluorescence Detection Platform project, and ventured into the microfluidic technology field.
Botuo Biotech Report for the Third Quarter of 2024
Botao Biology (688767.SH): Plans to launch an employee stock ownership plan in 2024.
Galaxy Comprehensive News September 25th | Botuo Biotechnology (688767.SH) announced the 2024 employee stock ownership plan, the stocks in this employee stock ownership plan come from the company's repurchase special account to repurchase Botuo Biotechnology A ordinary shares. The target stocks to be held in this employee stock ownership plan will not exceed 2.15 million shares, accounting for approximately 2.02% of the total 106.666667 million shares of the company's capital stock on the date the draft of this employee stock ownership plan was announced. The funds for this employee stock ownership plan come from legitimate employee compensation, self-raised funds, and other methods allowed by laws and regulations. The company does not provide financial assistance or loans to shareholders.
Hangzhou Biotest BiotechLtd's (SHSE:688767) Shareholders May Want To Dig Deeper Than Statutory Profit
Summary of Botuo Biotech\'s 2024 Semi-Annual Report
Botuo Biotech 2024 Semi-Annual Report
Biotrack (688767.SH) released its semi-annual performance, with a net income of 72.18 million yuan, a year-on-year increase of 17.16%.
Biotech (688767.SH) disclosed its 2024 interim report, during the reporting period the company achieved revenue of 2.67...
Botao Biology (688767.SH): The net income in the first half of the year was 72.1751 million yuan, a year-on-year increase of 17.16%.
On August 29, Golonghui announced its semi-annual report for 2024, with operating revenue of 0.267 billion yuan, a year-on-year increase of 25.97%; net income attributable to shareholders of the listed company was 72.1751 million yuan, a year-on-year increase of 17.16%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 70.1048 million yuan, a year-on-year increase of 31.57%; basic earnings per share were 0.69 yuan.
Botu Biological (688767.SH): Cumulative repurchase of 2.02% of shares, the buyback plan has been completed.
On July 24th, Gelonhui announced that the company's share buyback plan has been completed as of the date of this announcement. The company has repurchased a total of 2,150,000 shares through centralized bidding trading, accounting for 2.02% of the company's total share capital. The highest purchase price was 33.48 yuan/share, the lowest was 22.23 yuan/share, and the average purchase price was 26.95 yuan/share. The total amount paid was RMB 57,949,678.66 (excluding stamp duty, transaction fees, and other expenses).
Biotools (688767.SH): spent a total of 56.93 million yuan to repurchase 1.978% of the shares.
On July 1st, Gelunhui reported that Botro Biotechnology (688767.SH) had repurchased a total of 2,109,838 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading as of June 30, 2024, accounting for 1.9780% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of funds paid was RMB 56,930,164.60 (excluding stamp duty, transaction commission and other transaction fees).
Botuo Biotech (688767.SH) will distribute 8 yuan for every 10 shares in 2023. The stock registration date is June 7
Botuo Biotech (688767.SH) announced that the company will implement the 2023 annual equity distribution to all shares...
Botuo Biotech (688767.SH): Has repurchased a total of 2.109,800 shares of the company's shares
Gelonghui, June 2, 丨 Botuo Biotech (688767.SH) announced that as of May 31, 2024, the company had repurchased 2.109,800 shares of the company's shares through centralized bidding transactions, accounting for 1.9780% of the company's total share capital. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 569.32 million (excluding transaction fees such as stamp duty and transaction fees).
Botuo Biotech (688767.SH): Currently, POCT industry competition is fierce, and POCT products are under pressure to reduce prices
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that currently the POCT industry is fiercely competitive, and POCT products are under certain price reduction pressure.
Botuo Biotech (688767.SH): Will continue to focus on POCT testing tracks
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the company will continue to focus on the POCT testing circuit, give full play to the technology, product, quality and sales advantages that the company has accumulated over the years, and launch new products with higher cost performance, higher sensitivity, and closer to customer usage needs in colloidal gold technology. In terms of new technology platforms, efforts are being made to expand the variety of immunofluorescence products, increase the number of registration certificates for immunofluorescence products, further improve product quality through microfluidic control technology, and create new technology products with differentiated advantages. At the same time, the company is working hard to find the right shape on the outside
Botuo Biotech (688767.SH): COVID-19 related assets have been prepared for depreciation in 2023
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that the total asset impairment losses calculated by the company in 2023 were 588.364 million yuan, mainly inventory impairment losses, with a small portion being credit impairment losses. COVID-19 related assets have been prepared for depreciation in 2023 and will not have an impact on subsequent reporting periods.
Botuo Biotech (688767.SH): Domestic sales of influenza A and B testing products achieved rapid growth in 2023. Non-COVID-19 infectious disease series products increased 84.98% year-on-year
Gelonghui, May 13丨Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the operating revenue of drug testing and infectious disease testing series products in 2023 accounts for more than 80% of the company's total revenue. Domestic sales of influenza A and B testing products achieved rapid growth in 2023. Non-COVID-19 infectious disease series products increased by 84.98% over the same period last year. The drug abuse (drug) testing series products also achieved a certain increase over the same period last year.